Biosign Technologies has transformed from a medical device company to an international Cloud Based Medical SaaS provider.
Our cutting edge technology is transforming how Healthcare is being delivered in Germany and we have a suite of products under our new AioCare brand.
The innovative AioMed-software is unique in Germany and provides comprehensive solutions for the health care system. A continuing shortage of caretakers and doctors results in a lack of time and brings a loss of quality for the patient care. The AioMed-software optimizes the communication and administration processes and brings obvious cost- and time savings for the entire care sector.
Michael Gross is a Professor of Surgery at Dalhousie University Department of Surgery. He is the Medical Director of the Tissue Bank and served as President of the Medical staff of CDHA for three years.
He has worked with the Orthopaedic Industry in implant design and has developed new technology for clinical use.
He is ICD.D certified from the Institute of Corporate Directors and served as lead Director of Brigus Gold prior to its sale in 2014. He now sits on the Board of Fortune Bay. He has served as a director of the Halifax First Angel Network and as a mentor in the "Starting Lean" program at the Business School at Dalhousie University.
A senior technology executive with many years of international experience working with public and private technology companies. Mr. Hamilton has served as President, CEO, Chairman and held various senior executive roles with several notable technology companies including SoftKey Software (Learning Company), which grew from a startup to over US $800 million in annual revenue during his tenure as a Director and the SVP of Operations.
Mr. Hamilton also served as CEO of Europe for the Innovation Group, where he established a Pan-European presence with offices throughout the UK as well as Brussels, Stuttgart, Paris and Barcelona. Mr. Hamilton has a solid track record in M&A and Corporate Finance and has worked extensively in Canada, the United States, England and Germany.
A seasoned finance professional with international experience with publicly-traded and privately-held technology companies. Successful in both turnaround and high growth environment, Mr. Laflamme was a senior executive instrumental in the growth of SoftKey Software (Learning Company) and the turnaround of Prodigy. SoftKey grew to over US $800 million in revenue prior to being acquired by Mattel for $3.6 billion and Prodigy was acquired by SBC Telecommunications subsequent to its IPO. Mr. Laflamme has helped raise over $100 million in private equity and venture funding during his career and has substantial merger and acquisitions experience in both buy and sell side. Mr. Laflamme has worked in Canada and the United States and is a dual citizen.
A senior Business Development, Strategic Alliances & Sales executive .
Over twenty-five years with IT companies serving the Telecom, Financial & Insurance Services & Health care. John grew Tier 1 strategic alliances with global systems integrators (IBM, Accenture) for leading California based enterprise software companies, and held executive roles within the Health and Wellness and Home Care Sectors. John recently served as Acting President of Q Line Solutions, a leading Canadian Homecare Technology provider, where he orchestrated a successful turnaround.
Mr. Schumacher served as VP with Advanced Systems – Bell Canada, VP – Bus Dev. – Genesys Canada, VP & Director – Global Strategic Alliances (Kana, Chordiant, Innovation Group) and as Director - Sales & Bus. Dev. – applepeak, a wellness and health care technology company that Biosign acquired their technology rights from.
High-Honors Diploma (Computer Programming and Systems Analysis) Seneca College – Toronto.
Mr. Marney is an experienced international business executive with a wide range of commercial, finance & operations experience. He most recently served as CEO of ClinicServer, a cloud based practice management SaaS software solution for the Physiotherapy & Allied Health market place in North America, where he led a successful turnaround that allowed Biosign to sell the division for over 300% ROI in July of 2015.
Prior to that Mr. Marney served as a Managing Director of BioSign Europe GmbH in Frankfurt, Germany and was involved in the acquisition and integration of a controlling stake of AioMed GmbH. Mr. Marney was previously focused on M&A, investment banking, corporate finance and consulting acting in a senior leadership capacity since 1999. his prior career was focused on the high tech and telecom sectors with various technology and leadership roles with companies such as Bell Canada, Nortel and NBTel and Aliant Telecom.
Bachelors of Science in Business with a major in Operation Research and minor in Accounting from DeVry University in Phoenix, Arizona.
Mr. Ball is a long term service technology professional in Germany and throughout Europe and is a founder of AioMed GmbH.
The concept of AioMed started when Mr. Ball decided to use his technology expertise to fix the way care was delivered in Germany after losing a loved one. It took years of hard work and toil to get the product to commercialization stage and that is when Biosign acquired a stake in AioMed to become an international strategic partner and help make Mr. Ball’s dream a commercial success.
Mr. Ball’s prior career consisted of working in high level R&D projects, product development, project management & data and network security for British Telecom, T-Mobile and others. He has over 25 years of experience.
He holds a bachelors or science in computer science that he received from the University of Darmstadt.
Mr. Butzinger has a long track record of Senior and Executive level roles for notable international medical diagnostics, pharmaceutical and Medical Technology companies both in Germany and the United States. He is a founder and Managing Director of MedVec International which has had a long standing relationship with Biosign Technologies having held various license agreements for Biosign products in Europe.
Mr. Butzinger had a career focus on strategic transactions doing licensing and acquisition deals within Europe for Proprius Pharmaceuticals and was also involved in the notable success of Prometheus Therapeutics and Diagnostics operating their European and International markets. Prior to that Mr. Butzinger headed up various divisions and business units in Germany, Europe and globally for Quidell Corporation and executive sales roles at Eppendorf while living in San Diego.